HealthLawProf Blog

Editor: Katharine Van Tassel
Akron Univ. School of Law

A Member of the Law Professor Blogs Network

Wednesday, September 26, 2012

Reporting information about clinical trial data: passing the torch from HHS to the FDA

In 2007, motivated by concerns that pharmaceutical companies were not sharing negative data about what had been learned in clinical trials, Congress established enhanced reporting requirements, http://prsinfo.clinicaltrials.gov/s801-fact-sheet.pdf.

A series of articles published in January 2012 in the British Medical Journal demonstrates that data reporting remains deeply problematic, especially for industry-sponsored trials. (The articles can be found at http://www.bmj.com/content/344/bmj.d8013?tab=related and are very much worth reading). 

A posting Sept. 26 in the Federal Register indicates that the Secretary of HHS has delegated authority to to oversee the reporting process to the FDA, https://s3.amazonaws.com/public-inspection.federalregister.gov/2012-23598.pdf.  Whether this signals improved monitoring of clinical trial data submissions remains to be seen, http://www.pharmalot.com/2012/09/fda-gets-new-authority-over-clinical-trial-reporting/.  One can only hope.

[LPF]

http://lawprofessors.typepad.com/healthlawprof_blog/2012/09/reporting-information-about-clinical-trial-data-passing-the-torch-from-hhs-to-the-fda.html

| Permalink

TrackBack URL for this entry:

http://www.typepad.com/services/trackback/6a00d8341bfae553ef017d3c55f7db970c

Listed below are links to weblogs that reference Reporting information about clinical trial data: passing the torch from HHS to the FDA:

Comments

Post a comment